Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus

Shao Hui; Zhai Suodi; Zou Dajin; Mir Mohammed Umer; Zawadzki Nadine K.; Shi Qian; Liu Shuqian; Shi Lizheng

首页> 外文期刊>Current medical research and opinion >Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus

【24h】

Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus

机译：Dapagliflozin与Glimepiride的成本效果分析，作为2型糖尿病的中国人群的单药治疗

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objective: To evaluate the long-term cost-effectiveness of dapagliflozin (a novel sodium- glucose co-transporter-2 inhibitor) versus glimepiride (a widely used sulfonylurea), when applied as monotherapy in patients with type 2 diabetes mellitus (T2DM) in China.

机译：目的：评价Dapagliflozin（一种新型葡萄糖共转运蛋白-2抑制剂）与胶质素（广泛使用的磺酰脲）的长期成本效果，当患有2型糖尿病（T2DM）的单一疗法时中国。

著录项

来源
《Current medical research and opinion》 |2017年第2期|共11页
作者
Shao Hui; Zhai Suodi; Zou Dajin; Mir Mohammed Umer; Zawadzki Nadine K.; Shi Qian; Liu Shuqian; Shi Lizheng;
展开▼
作者单位

Tulane Univ Sch Publ Hlth &

Trop Med Dept Global Hlth Management &

Policy New Orleans LA 70118;

Peking Univ Hosp 3 Dept Pharm Beijing Peoples R China;

Second Mil Med Univ Changhai Hosp Dept Endocrinol Shanghai Peoples R China;

Tulane Univ Sch Publ Hlth &

Trop Med Dept Global Hlth Management &

Policy New Orleans LA 70118;

Tulane Univ Sch Publ Hlth &

Trop Med Dept Global Hlth Management &

Policy New Orleans LA 70118;

Tulane Univ Sch Publ Hlth &

Trop Med Dept Global Hlth Management &

Policy New Orleans LA 70118;

Tulane Univ Sch Publ Hlth &

Trop Med Dept Global Hlth Management &

Policy New Orleans LA 70118;

Tulane Univ Sch Publ Hlth &

Trop Med Dept Global Hlth Management &

Policy New Orleans LA 70118;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词
Cost-effectiveness; dapagliflozin; glimepiride; monotherapy; type 2 diabetes mellitus;

机译：成本效益;Dapagliflozin;Glimepiride;单药治疗;2型糖尿病;

相似文献

外文文献
中文文献
专利

1. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus [J] . Shao Hui, Zhai Suodi, Zou Dajin, Current medical research and opinion . 2017,第2期

机译：Dapagliflozin与Glimepiride的成本效果分析，作为2型糖尿病的中国人群的单药治疗
2. DAPAGLIFLOZIN VERSUS SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN COLOMBIA: COST-EFFECTIVENESS ANALYSIS [J] . Ordonez J. E. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：Dapagliflozin与磺脲类患者患有2型糖尿病患者哥伦比亚：成本效益分析
3. LIRAGLUTIDE VERSUS DAPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE-2 DIABETES MELLITUS IN SPAIN: A COST-EFFECTIVENESS ANALYSIS [J] . de Arellano Serna Ramirez A., Mezquita-Raya P., Vega-Hernandez G., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：利拉鲁肽对DAPAGLIFLOZIN治疗西班牙2型糖尿病的患者：成本-效果分析
4. Urinary Inorganic Arsenic Concentration and Type 2 Diabetes Mellitus and Hypertension Development: A Population-Based Analysis in Arica, Chile [C] . Maria P. Munoz, Paola A. Rubilar, Macarena Valdes, Joint annual meeting of the International Society of Exposure Science and the International Society for Environmental Epidemiology . 2018

机译：尿无机砷浓度和2型糖尿病与高血压的发展：在智利的阿里卡，基于人群的分析
5. An analysis of the long-term cost-effectiveness of intensive lifestyle intervention for type 2 diabetes mellitus prevention. [D] . Novak, Suzanne. 2005

机译：强化生活方式干预预防2型糖尿病的长期成本效益分析。
6. Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China [O] . Shuyan Gu, Yiming Mu, Suodi Zhai, -1

机译：Dapagliflozin对比阿卡波糖单药治疗中国2型糖尿病的成本效益
7. Cost-Effectiveness Analysis of Dapagliflozin Versus Glimepiride as Monotherapy in Patients with Type 2 Diabetes Mellitus in China [O] . H Shao, L Shi 2016

机译：Dapagliflozin与Glimepiride为单药治疗2型糖尿病患者的成本效果分析

Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus

摘要

著录项

相似文献

相关主题

期刊订阅